Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
US9347937B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 14, 2013 |
| Grant date | May 24, 2016 |
| Priority date | — |
| Expiry date | Jun 14, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/24
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.